Figure 5. Neutralization of Oropouche virus strains BeAn 19991 and AM0088 by PRNT₅₀.

(A) Serum samples were tested by PRNT₅₀ in Vero CCL81 cells after incubation with OROV strain BeAn 19991 or AM0088. PRNT₅₀ represents the sample dilution that showed a 50% reduction in plaque formation compared with a control well inoculated with OROV alone (without serum), after linear regression analysis. Each data point represents the mean of all serum samples for each group at each dilution level (shown as log₂ serum dilution), and error bars represent SD (left). PRNT₅₀ titer that is defined as the reciprocal value of the serum dilution that reduced cytopathic effects by 50% against cytopathic effects (right). (A). Serum samples individuals previously infected with OROV in Coari, Amazonas State, Brazil (n=22). (B). Serum samples were collected from C57BL/6 mice 28 days after infection with OROV strain AM0088 (n=7). (C). Serum samples were collected from C57BL/6 mice 28 days after infection with OROV strain BeAn 19991 (n=5).